Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Multiple Myeloma
60%
Multiple Myeloma Patients
36%
Overall Survival
34%
Acute Myeloid Leukemia
27%
Relapsed/refractory multiple Myeloma
26%
Autologous Stem Cell Transplantation (auto-SCT)
25%
Progression-free Survival
24%
Autologous Transplantation
22%
Chimeric Antigen Receptor T Cells (CAR-T)
19%
Newly Diagnosed multiple Myeloma
19%
Pretransplant
18%
High-risk Myeloma
17%
Patient Outcomes
15%
Diffuse Large B-cell Lymphoma (DLBCL)
15%
Very Good Partial Response
15%
Tyrosine Kinase Inhibitor
15%
Minimal Residual Disease
14%
Lenalidomide
14%
High-risk Cytogenetics
14%
Teclistamab
13%
Hazard Ratio
12%
Maintenance Therapy
12%
Chronic Myeloid Leukemia
12%
Hematopoietic Cell Transplantation
12%
Median Progression-free Survival
11%
Lenalidomide Maintenance
11%
Diagnostic Yield
11%
95% Confidence Interval
11%
Leukemia Patients
11%
Post-transplant Management
11%
Non-relapse Mortality
10%
Myelodysplastic Syndrome
10%
Allogeneic
10%
Ponatinib
10%
Single Center
9%
Median Overall Survival
9%
High Risk
9%
Standard of Care
8%
Multivariate Analysis
8%
Hemophagocytic Lymphohistiocytosis
8%
Brexucabtagene Autoleucel
8%
Bortezomib
7%
Tertiary Care Centers
7%
Heavily Pretreated
7%
Israeli
7%
Sorafenib
7%
Single-center Experience
7%
Retrospective Analysis
7%
Newly Diagnosed
7%
Medicine and Dentistry
Multiple Myeloma
94%
Hematopoietic Cell
41%
Overall Survival
38%
Cell Transplantation
37%
Progression Free Survival
34%
Autologous Hematopoietic Stem Cell Transplantation
33%
Diseases
26%
Stem Cell Transplant
20%
Lenalidomide
19%
Diffuse Large B-Cell Lymphoma
19%
Autologous Stem Cell Transplantation
15%
Retrospective Study
15%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Median Follow Up
14%
Acute Myeloid Leukemia
14%
Malignant Neoplasm
13%
Hematopoietic Stem Cell Transplantation
13%
Tyrosine-Kinase Inhibitor
12%
Immunotherapy
11%
Minimal Residual Disease
11%
Chronic Myelogenous Leukemia
11%
Autotransplantation
10%
Myeloma
10%
Hazard Ratio
9%
Infection
9%
Multivariate Analysis
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
9%
Immunoglobulin Producing Cell
8%
Maintenance Therapy
8%
Comorbidity
8%
Non-Relapse Mortality
7%
Chemotherapy
7%
Dexamethasone
7%
Ponatinib
6%
Venetoclax
6%
Autograft
6%
Antiinfective Agent
6%
Biopsy Technique
6%
Premature Aging
6%
Acute Myelogenous Leukemia
6%
COVID-19
6%
Bortezomib
6%
Flow Cytometry
6%
Dasatinib
5%
Adolescence
5%
Univariate Analysis
5%
Imatinib
5%
Bosutinib
5%
Nilotinib
5%
Adverse Event
5%
Immunology and Microbiology
Multiple Myeloma
92%
Hematopoietic Cell
47%
Cell Transplantation
44%
Overall Survival
42%
Progression Free Survival
36%
Autologous Hematopoietic Stem Cell Transplantation
30%
Lenalidomide
25%
Myeloid
24%
Immunotherapy
21%
B Cell
19%
Infection
13%
Infectious Disease
12%
Autologous Stem Cell Transplantation
11%
Autotransplantation
11%
Chimeric Antigen Receptor T-Cell Therapy
10%
B Cell Maturation Antigen
9%
Hematopoietic Stem Cell Transplantation
9%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Immunoglobulin Producing Cell
8%
Dexamethasone
8%
Sorafenib
7%
Bispecific Antibody
7%
Stem Cell Transplant
6%
Hemophagocytic Lymphohistiocytosis
6%
Autograft
6%
Autoantibodies
6%
COVID-19
6%
Tyrosine
6%
Phosphotransferase
5%
Kinase
5%
Engraftment
5%